Uveitis - Pipeline Review, H2 2017

Published: Sep, 2017 | Pages: 208 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveitis - Pipeline Review, H2 2017, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 5, 8, 5, 2, 25, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Uveitis - Overview 8
Uveitis - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 19
Uveitis - Therapeutics Assessment 20
Assessment by Target 20
Assessment by Mechanism of Action 23
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Uveitis - Companies Involved in Therapeutics Development 30
2-BBB Medicines BV 30
AbbVie Inc 30
Aciont Inc 31
Alcon Laboratories Inc 31
Aldeyra Therapeutics Inc 31
Apitope International NV 32
Bionomics Ltd 32
Bristol-Myers Squibb Co 33
Can-Fite BioPharma Ltd 33
Clearside BioMedical Inc 34
Coherus BioSciences Inc 34
Elasmogen Ltd 35
Endocyte Inc 35
Enzo Biochem Inc 35
EyeGate Pharmaceuticals Inc 36
Eyevensys SAS 36
F. Hoffmann-La Roche Ltd 37
Galapagos NV 37
HanAll Biopharma Co Ltd 38
Icon Bioscience Inc 38
Idera Pharmaceuticals Inc 38
Johnson & Johnson 39
KPI Therapeutics Inc 39
Midatech Pharma Plc 40
Mitotech SA 40
Nemus Bioscience Inc 41
Novartis AG 41
Oculis ehf 42
OncoNOx ApS 42
Ophthotech Corp 42
Orchid Pharma Ltd 43
Palatin Technologies Inc 43
Panoptes Pharma GesmbH 44
pSivida Corp 44
Re-Pharm Ltd 45
Santen Pharmaceutical Co Ltd 45
SynDevRx Inc 45
TxCell SA 46
Uveitis - Drug Profiles 47
2B-3201 - Drug Profile 47
abatacept - Drug Profile 49
adalimumab - Drug Profile 58
adalimumab biosimilar - Drug Profile 67
adalimumab biosimilar - Drug Profile 70
adalimumab biosimilar - Drug Profile 73
adalimumab biosimilar - Drug Profile 74
ADX-102 - Drug Profile 75
Antisense Oligonucleotide to Inhibit NLRP3 for Inflammatory Disorders - Drug Profile 81
Antisense RNAi Oligonucleotide to Inhibit ProRenin Receptor for Uveitis and Diabetic Retinopathy - Drug Profile 82
ANV-103 - Drug Profile 83
ATXUV-1 - Drug Profile 84
avacincaptad pegol sodium - Drug Profile 85
B27-PD - Drug Profile 88
BNC-164 - Drug Profile 89
Col-Treg - Drug Profile 90
CVX-001 - Drug Profile 92
cyclosporine SR - Drug Profile 93
dalazatide - Drug Profile 94
dexamethasone acetate - Drug Profile 99
dexamethasone acetate - Drug Profile 105
dexamethasone sodium phosphate - Drug Profile 107
Drug for Chronic Uveitis - Drug Profile 109
Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile 110
EBI-031 - Drug Profile 111
EC-1669 - Drug Profile 112
ELN-21 - Drug Profile 113
ELN-22 - Drug Profile 114
EYS-606 - Drug Profile 115
filgotinib - Drug Profile 116
fluocinolone acetonide SA - Drug Profile 129
fluocinolone acetonide SR - Drug Profile 130
FR-104 - Drug Profile 139
Gene Therapy for Dry Age-Related Macular Degeneration and Uveitis - Drug Profile 142
HL-036 - Drug Profile 143
HO-10 - Drug Profile 144
IVMED-10 - Drug Profile 145
IVMED-20 - Drug Profile 146
KPI-190 - Drug Profile 147
latanoprost SR - Drug Profile 148
LME-636 - Drug Profile 149
lodamin - Drug Profile 150
methotrexate - Drug Profile 151
NB-2222 - Drug Profile 152
OX-1001 - Drug Profile 153
piclidenoson - Drug Profile 154
PL-8177 - Drug Profile 164
plastoquinone decyl triphenylphosphonium bromide - Drug Profile 165
PP-001 - Drug Profile 167
PPL-003 - Drug Profile 169
RP-0217 - Drug Profile 171
sirolimus - Drug Profile 172
Small Molecule to Inhibit PDE4B and TNF Alpha for Asthma, COPD and Uveitis - Drug Profile 176
Small Molecules to Inhibit 5-Lipoxygenase for Uveitis - Drug Profile 177
Small Molecules to Inhibit TYK2 for Psoriasis and Uveitis - Drug Profile 178
tesidolumab - Drug Profile 179
triamcinolone acetonide - Drug Profile 181
Uveitis - Dormant Projects 188
Uveitis - Discontinued Products 191
Uveitis - Product Development Milestones 192
Featured News & Press Releases 192
Appendix 203
Methodology 203
Coverage 203
Secondary Research 203
Primary Research 203
Expert Panel Validation 203
Contact Us 203
Disclaimer 204

List of Tables

Number of Products under Development for Uveitis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Uveitis - Pipeline by 2-BBB Medicines BV, H2 2017
Uveitis - Pipeline by AbbVie Inc, H2 2017
Uveitis - Pipeline by Aciont Inc, H2 2017
Uveitis - Pipeline by Alcon Laboratories Inc, H2 2017
Uveitis - Pipeline by Aldeyra Therapeutics Inc, H2 2017
Uveitis - Pipeline by Apitope International NV, H2 2017
Uveitis - Pipeline by Bionomics Ltd, H2 2017
Uveitis - Pipeline by Bristol-Myers Squibb Co, H2 2017
Uveitis - Pipeline by Can-Fite BioPharma Ltd, H2 2017
Uveitis - Pipeline by Clearside BioMedical Inc, H2 2017
Uveitis - Pipeline by Coherus BioSciences Inc, H2 2017
Uveitis - Pipeline by Elasmogen Ltd, H2 2017
Uveitis - Pipeline by Endocyte Inc, H2 2017
Uveitis - Pipeline by Enzo Biochem Inc, H2 2017
Uveitis - Pipeline by EyeGate Pharmaceuticals Inc, H2 2017
Uveitis - Pipeline by Eyevensys SAS, H2 2017
Uveitis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Uveitis - Pipeline by Galapagos NV, H2 2017
Uveitis - Pipeline by HanAll Biopharma Co Ltd, H2 2017
Uveitis - Pipeline by Icon Bioscience Inc, H2 2017
Uveitis - Pipeline by Idera Pharmaceuticals Inc, H2 2017
Uveitis - Pipeline by Johnson & Johnson, H2 2017
Uveitis - Pipeline by KPI Therapeutics Inc, H2 2017
Uveitis - Pipeline by Midatech Pharma Plc, H2 2017
Uveitis - Pipeline by Mitotech SA, H2 2017
Uveitis - Pipeline by Nemus Bioscience Inc, H2 2017
Uveitis - Pipeline by Novartis AG, H2 2017
Uveitis - Pipeline by Oculis ehf, H2 2017
Uveitis - Pipeline by OncoNOx ApS, H2 2017
Uveitis - Pipeline by Ophthotech Corp, H2 2017
Uveitis - Pipeline by Orchid Pharma Ltd, H2 2017
Uveitis - Pipeline by Palatin Technologies Inc, H2 2017
Uveitis - Pipeline by Panoptes Pharma GesmbH, H2 2017
Uveitis - Pipeline by pSivida Corp, H2 2017
Uveitis - Pipeline by Re-Pharm Ltd, H2 2017
Uveitis - Pipeline by Santen Pharmaceutical Co Ltd, H2 2017
Uveitis - Pipeline by SynDevRx Inc, H2 2017
Uveitis - Pipeline by TxCell SA, H2 2017
Uveitis - Dormant Projects, H2 2017
Uveitis - Dormant Projects, H2 2017 (Contd..1), H2 2017
Uveitis - Dormant Projects, H2 2017 (Contd..2), H2 2017
Uveitis - Discontinued Products, H2 2017